Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease

Clinics

Volumn 64, Issue 4, 2009, Pages 323-326

  Zanati, Silméia Garcia ^a   Mouraria, Guilherme Grisi ^a   Matsubara, Luiz Shigero ^a   Giannini, Mariângela ^a   Matsubara, Beatriz B ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Aspirin; Cardiovascular risk; Elderly; Smoking; Vascular surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; BRAZIL; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SURVIVAL;

AGED; ASPIRIN; BRAZIL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIERS ESTIMATE; MALE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 67650607185     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009000400010     Document Type: Article

References (19)

1. Ouriel K. Peripheral artery disease. Lancet 2001;358:1257-64.
2. Belch JJF, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Critical issues in peripheral arterial disease detection and management. A call for action. Arch Intern Med. 2003;163:884-92.
3. Murabito JM, D' Agostinho RB, Silbershartz H, Wilson WJ. Intermitent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997 Jul 1;96(1):44-9.
4. Strong JP. Atherosclerosis lesions. Natural history, risk factors and topography. Arch Pathol Lab Med. 1992;116:1268-75.
5. Janes SEJ, West J, Hopkinson BR, Walsh JT. Pharmacological secondary prevention in people with peripheral arterial disease compared to those with coronary artery disease: a missed opportunity. Br J Cardiol. 2008;15:48-50.
6. Hirsch AT, Halverson SL, Jacobson DT, Hotvedt PS, Lunzer MM, Krook S, et al. The Minnesota regional peripheral arterial disease screening program: toward a definition of community standards of care. Vasc Med. 2001;6:87-96.
7. Faxon DP, Creage MA, Smith SC, Pasternak RCJ, Olin JW, Bettmann MA, et al. Atherosclerotic Vascular Disease Conference. Executive Summary: Atherosclerotic Vascular Disease Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association. Circulation. 2004;109:2595-604.
8. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and Cardiovascular Disease: a Statement for Healthcare Professionals from the American Heart Association. Circulation.1999; 100:1134-46.
9. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW Jr. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg. 2005;41:816-22.
10. Mukherjee D, Lingman P, Chetcuti S, Grossman PM, Luciano AE, Eagle KA, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation. 2002;106:1909-12.
11. Smith SC Jr, Allen J, Blair SN. J Am Coll Cardiol. 2006;47:2130-4.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-63.
13. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1:217-9.
14. American Lung Association. Trends in tobacco use. New York, NY: American Lung Association, Epidemiology and Statistics Unit; 2001.
15. Wachtel Kl, Rokkedal J, Bella JN, Aalto T, Dahlöf B, Smith G, et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE Study). Am J Cardiol. 2001;87:54-60.
16. Stiefel P, Miranda ML, Rodriguez-Puras MJ, Garci ́a-Morillo S, Carneado J, Pamies E, et al. Glucose effectiveness is strongly related to left ventricular mass in subjects with stage I hypertension or high-normal blood pressure. Am J Hypertension. 2004;17:146-53.
17. Felicio JS, Pacheco JT, Ferreira SR, Plavnik F, Moise ́s VA, Kohlmann OJ, et al. Hyperglycemia and nocturnal systolic blood pressure are associated with left ventricular hypertrophy and diastolic dysfunction in hypertensive diabetic patients. Cardiovasc Diabetol. 2006;5:19.
18. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, et al. Importance of Heart Failure with Preserved Systolic Function in patients after 65 years of age. Am J Cardiol. 2001;87:413-9.
19. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF 3rd, Graor RA, et al. Coronary artery disease in peripheral vascular patients: a classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199(2):223-33.